Trinity Biotech (NASDAQ:TRIB) Lifted to “Hold” at ValuEngine

ValuEngine upgraded shares of Trinity Biotech (NASDAQ:TRIB) from a sell rating to a hold rating in a research report sent to investors on Tuesday, ValuEngine reports.

Shares of TRIB stock traded up $0.03 on Tuesday, reaching $0.95. 85,100 shares of the stock were exchanged, compared to its average volume of 68,603. Trinity Biotech has a one year low of $0.63 and a one year high of $3.99. The company has a current ratio of 3.13, a quick ratio of 1.97 and a debt-to-equity ratio of 2.10. The stock has a 50 day moving average price of $1.00 and a 200 day moving average price of $1.75.

Trinity Biotech (NASDAQ:TRIB) last released its earnings results on Wednesday, October 16th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The firm had revenue of $24.59 million for the quarter. Trinity Biotech had a negative return on equity of 10.96% and a negative net margin of 31.56%.

An institutional investor recently raised its position in Trinity Biotech stock. Renaissance Technologies LLC increased its stake in shares of Trinity Biotech plc (NASDAQ:TRIB) by 11.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 685,496 shares of the company’s stock after purchasing an additional 71,685 shares during the period. Renaissance Technologies LLC owned approximately 2.85% of Trinity Biotech worth $1,131,000 as of its most recent SEC filing. Institutional investors own 49.16% of the company’s stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.

Featured Article: What is the CBOE Russell 2000® Volatility Index?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.